Serveur d'exploration sur l'Université de Trèves

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

Identifieur interne : 001916 ( Istex/Corpus ); précédent : 001915; suivant : 001917

Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

Auteurs : Laura Ottaviano ; Karl-Ludwig Schaefer ; Melanie Gajewski ; Wolfgang Huckenbeck ; Stefan Baldus ; Uwe Rogel ; Carlos Mackintosh ; Enrique De Alava ; Ola Myklebost ; Stine H. Kresse ; Leonardo A. Meza-Zepeda ; Massimo Serra ; Anne-Marie Cleton-Jansen ; Pancras C. W. Hogendoorn ; Horst Buerger ; Thomas Aigner ; Helmut E. Gabbert ; Christopher Poremba

Source :

RBID : ISTEX:E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9

Abstract

Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of CDKN2A as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the TP53 gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53. TP53wt cell lines usually expressed the protein in 2–10% of the cells. However, seven TP53wt osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for CDKN2A and TP53, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable. © 2009 Wiley‐Liss, Inc.

Url:
DOI: 10.1002/gcc.20717

Links to Exploration step

ISTEX:E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
<author>
<name sortKey="Ottaviano, Laura" sort="Ottaviano, Laura" uniqKey="Ottaviano L" first="Laura" last="Ottaviano">Laura Ottaviano</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Schaefer, Karl Udwig" sort="Schaefer, Karl Udwig" uniqKey="Schaefer K" first="Karl-Ludwig" last="Schaefer">Karl-Ludwig Schaefer</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Institute of Pathology, Heinrich‐Heine‐University Duesseldorf, Germany, Moorenstr. 5, 40225 Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gajewski, Melanie" sort="Gajewski, Melanie" uniqKey="Gajewski M" first="Melanie" last="Gajewski">Melanie Gajewski</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Huckenbeck, Wolfgang" sort="Huckenbeck, Wolfgang" uniqKey="Huckenbeck W" first="Wolfgang" last="Huckenbeck">Wolfgang Huckenbeck</name>
<affiliation>
<mods:affiliation>Institute of Forensic Medicine, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Baldus, Stefan" sort="Baldus, Stefan" uniqKey="Baldus S" first="Stefan" last="Baldus">Stefan Baldus</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Rogel, Uwe" sort="Rogel, Uwe" uniqKey="Rogel U" first="Uwe" last="Rogel">Uwe Rogel</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mackintosh, Carlos" sort="Mackintosh, Carlos" uniqKey="Mackintosh C" first="Carlos" last="Mackintosh">Carlos Mackintosh</name>
<affiliation>
<mods:affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="De Alava, Enrique" sort="De Alava, Enrique" uniqKey="De Alava E" first="Enrique" last="De Alava">Enrique De Alava</name>
<affiliation>
<mods:affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Myklebost, Ola" sort="Myklebost, Ola" uniqKey="Myklebost O" first="Ola" last="Myklebost">Ola Myklebost</name>
<affiliation>
<mods:affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Kresse, Stine H" sort="Kresse, Stine H" uniqKey="Kresse S" first="Stine H." last="Kresse">Stine H. Kresse</name>
<affiliation>
<mods:affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Meza Epeda, Leonardo A" sort="Meza Epeda, Leonardo A" uniqKey="Meza Epeda L" first="Leonardo A." last="Meza-Zepeda">Leonardo A. Meza-Zepeda</name>
<affiliation>
<mods:affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Serra, Massimo" sort="Serra, Massimo" uniqKey="Serra M" first="Massimo" last="Serra">Massimo Serra</name>
<affiliation>
<mods:affiliation>Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Cleton Ansen, Anne Arie" sort="Cleton Ansen, Anne Arie" uniqKey="Cleton Ansen A" first="Anne-Marie" last="Cleton-Jansen">Anne-Marie Cleton-Jansen</name>
<affiliation>
<mods:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hogendoorn, Pancras C W" sort="Hogendoorn, Pancras C W" uniqKey="Hogendoorn P" first="Pancras C. W." last="Hogendoorn">Pancras C. W. Hogendoorn</name>
<affiliation>
<mods:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Buerger, Horst" sort="Buerger, Horst" uniqKey="Buerger H" first="Horst" last="Buerger">Horst Buerger</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Muenster, Muenster, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Aigner, Thomas" sort="Aigner, Thomas" uniqKey="Aigner T" first="Thomas" last="Aigner">Thomas Aigner</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University of Leipzig, Leipzig, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gabbert, Helmut E" sort="Gabbert, Helmut E" uniqKey="Gabbert H" first="Helmut E." last="Gabbert">Helmut E. Gabbert</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Poremba, Christopher" sort="Poremba, Christopher" uniqKey="Poremba C" first="Christopher" last="Poremba">Christopher Poremba</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Center of Histopathology, Cytology and Molecular Diagnostics (CHCMD), Research Park Trier, Trier, Germany</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/gcc.20717</idno>
<idno type="url">https://api.istex.fr/document/E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001916</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001916</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
<author>
<name sortKey="Ottaviano, Laura" sort="Ottaviano, Laura" uniqKey="Ottaviano L" first="Laura" last="Ottaviano">Laura Ottaviano</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Schaefer, Karl Udwig" sort="Schaefer, Karl Udwig" uniqKey="Schaefer K" first="Karl-Ludwig" last="Schaefer">Karl-Ludwig Schaefer</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Institute of Pathology, Heinrich‐Heine‐University Duesseldorf, Germany, Moorenstr. 5, 40225 Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gajewski, Melanie" sort="Gajewski, Melanie" uniqKey="Gajewski M" first="Melanie" last="Gajewski">Melanie Gajewski</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Huckenbeck, Wolfgang" sort="Huckenbeck, Wolfgang" uniqKey="Huckenbeck W" first="Wolfgang" last="Huckenbeck">Wolfgang Huckenbeck</name>
<affiliation>
<mods:affiliation>Institute of Forensic Medicine, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Baldus, Stefan" sort="Baldus, Stefan" uniqKey="Baldus S" first="Stefan" last="Baldus">Stefan Baldus</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Rogel, Uwe" sort="Rogel, Uwe" uniqKey="Rogel U" first="Uwe" last="Rogel">Uwe Rogel</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mackintosh, Carlos" sort="Mackintosh, Carlos" uniqKey="Mackintosh C" first="Carlos" last="Mackintosh">Carlos Mackintosh</name>
<affiliation>
<mods:affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="De Alava, Enrique" sort="De Alava, Enrique" uniqKey="De Alava E" first="Enrique" last="De Alava">Enrique De Alava</name>
<affiliation>
<mods:affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Myklebost, Ola" sort="Myklebost, Ola" uniqKey="Myklebost O" first="Ola" last="Myklebost">Ola Myklebost</name>
<affiliation>
<mods:affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Kresse, Stine H" sort="Kresse, Stine H" uniqKey="Kresse S" first="Stine H." last="Kresse">Stine H. Kresse</name>
<affiliation>
<mods:affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Meza Epeda, Leonardo A" sort="Meza Epeda, Leonardo A" uniqKey="Meza Epeda L" first="Leonardo A." last="Meza-Zepeda">Leonardo A. Meza-Zepeda</name>
<affiliation>
<mods:affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Serra, Massimo" sort="Serra, Massimo" uniqKey="Serra M" first="Massimo" last="Serra">Massimo Serra</name>
<affiliation>
<mods:affiliation>Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Cleton Ansen, Anne Arie" sort="Cleton Ansen, Anne Arie" uniqKey="Cleton Ansen A" first="Anne-Marie" last="Cleton-Jansen">Anne-Marie Cleton-Jansen</name>
<affiliation>
<mods:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hogendoorn, Pancras C W" sort="Hogendoorn, Pancras C W" uniqKey="Hogendoorn P" first="Pancras C. W." last="Hogendoorn">Pancras C. W. Hogendoorn</name>
<affiliation>
<mods:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Buerger, Horst" sort="Buerger, Horst" uniqKey="Buerger H" first="Horst" last="Buerger">Horst Buerger</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Muenster, Muenster, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Aigner, Thomas" sort="Aigner, Thomas" uniqKey="Aigner T" first="Thomas" last="Aigner">Thomas Aigner</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University of Leipzig, Leipzig, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gabbert, Helmut E" sort="Gabbert, Helmut E" uniqKey="Gabbert H" first="Helmut E." last="Gabbert">Helmut E. Gabbert</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Poremba, Christopher" sort="Poremba, Christopher" uniqKey="Poremba C" first="Christopher" last="Poremba">Christopher Poremba</name>
<affiliation>
<mods:affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Center of Histopathology, Cytology and Molecular Diagnostics (CHCMD), Research Park Trier, Trier, Germany</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Genes, Chromosomes and Cancer</title>
<title level="j" type="abbrev">Genes Chromosom. Cancer</title>
<idno type="ISSN">1045-2257</idno>
<idno type="eISSN">1098-2264</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01">2010-01</date>
<biblScope unit="volume">49</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="40">40</biblScope>
<biblScope unit="page" to="51">51</biblScope>
</imprint>
<idno type="ISSN">1045-2257</idno>
</series>
<idno type="istex">E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9</idno>
<idno type="DOI">10.1002/gcc.20717</idno>
<idno type="ArticleID">GCC20717</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1045-2257</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of CDKN2A as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the TP53 gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53. TP53wt cell lines usually expressed the protein in 2–10% of the cells. However, seven TP53wt osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for CDKN2A and TP53, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable. © 2009 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<author>
<json:item>
<name>Laura Ottaviano</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Karl‐Ludwig Schaefer</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
<json:string>Institute of Pathology, Heinrich‐Heine‐University Duesseldorf, Germany, Moorenstr. 5, 40225 Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Melanie Gajewski</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Wolfgang Huckenbeck</name>
<affiliations>
<json:string>Institute of Forensic Medicine, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Stefan Baldus</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Uwe Rogel</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Carlos Mackintosh</name>
<affiliations>
<json:string>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</json:string>
</affiliations>
</json:item>
<json:item>
<name>Enrique de Alava</name>
<affiliations>
<json:string>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</json:string>
</affiliations>
</json:item>
<json:item>
<name>Ola Myklebost</name>
<affiliations>
<json:string>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</json:string>
</affiliations>
</json:item>
<json:item>
<name>Stine H. Kresse</name>
<affiliations>
<json:string>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</json:string>
</affiliations>
</json:item>
<json:item>
<name>Leonardo A. Meza‐Zepeda</name>
<affiliations>
<json:string>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</json:string>
</affiliations>
</json:item>
<json:item>
<name>Massimo Serra</name>
<affiliations>
<json:string>Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy</json:string>
</affiliations>
</json:item>
<json:item>
<name>Anne‐Marie Cleton‐Jansen</name>
<affiliations>
<json:string>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>Pancras C. W. Hogendoorn</name>
<affiliations>
<json:string>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>Horst Buerger</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Muenster, Muenster, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Thomas Aigner</name>
<affiliations>
<json:string>Institute of Pathology, University of Leipzig, Leipzig, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Helmut E. Gabbert</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
</affiliations>
</json:item>
<json:item>
<name>Christopher Poremba</name>
<affiliations>
<json:string>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</json:string>
<json:string>Center of Histopathology, Cytology and Molecular Diagnostics (CHCMD), Research Park Trier, Trier, Germany</json:string>
</affiliations>
</json:item>
</author>
<articleId>
<json:string>GCC20717</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>article</json:string>
</originalGenre>
<abstract>Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of CDKN2A as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the TP53 gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53. TP53wt cell lines usually expressed the protein in 2–10% of the cells. However, seven TP53wt osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for CDKN2A and TP53, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable. © 2009 Wiley‐Liss, Inc.</abstract>
<qualityIndicators>
<score>7.892</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>612 x 810 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>1613</abstractCharCount>
<pdfWordCount>5974</pdfWordCount>
<pdfCharCount>40860</pdfCharCount>
<pdfPageCount>12</pdfPageCount>
<abstractWordCount>241</abstractWordCount>
</qualityIndicators>
<title>Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
<refBibs>
<json:item>
<author>
<json:item>
<name>I Alldinger</name>
</json:item>
<json:item>
<name>KL Schaefer</name>
</json:item>
<json:item>
<name>D Goedde</name>
</json:item>
<json:item>
<name>L Ottaviano</name>
</json:item>
<json:item>
<name>U Dirksen</name>
</json:item>
<json:item>
<name>A Ranft</name>
</json:item>
<json:item>
<name>H Juergens</name>
</json:item>
<json:item>
<name>HE Gabbert</name>
</json:item>
<json:item>
<name>WT Knoefel</name>
</json:item>
<json:item>
<name>C Poremba</name>
</json:item>
</author>
<host>
<volume>133</volume>
<pages>
<last>759</last>
<first>749</first>
</pages>
<author></author>
<title>J Cancer Res Clin Oncol</title>
</host>
<title>Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression</title>
</json:item>
<json:item>
<author>
<json:item>
<name>S Benini</name>
</json:item>
<json:item>
<name>N Baldini</name>
</json:item>
<json:item>
<name>MC Manara</name>
</json:item>
<json:item>
<name>T Chano</name>
</json:item>
<json:item>
<name>M Serra</name>
</json:item>
<json:item>
<name>S Rizzi</name>
</json:item>
<json:item>
<name>PL Lollini</name>
</json:item>
<json:item>
<name>P Picci</name>
</json:item>
<json:item>
<name>K Scotlandi</name>
</json:item>
</author>
<host>
<volume>80</volume>
<pages>
<last>588</last>
<first>581</first>
</pages>
<author></author>
<title>Int J Cancer</title>
</host>
<title>Redundancy of autocrine loops in human osteosarcoma cells</title>
</json:item>
<json:item>
<author>
<json:item>
<name>SM Bodner</name>
</json:item>
<json:item>
<name>JD Minna</name>
</json:item>
<json:item>
<name>SM Jensen</name>
</json:item>
<json:item>
<name>D D'Amico</name>
</json:item>
<json:item>
<name>D Carbone</name>
</json:item>
<json:item>
<name>T Mitsudomi</name>
</json:item>
<json:item>
<name>J Fedorko</name>
</json:item>
<json:item>
<name>DL Buchhagen</name>
</json:item>
<json:item>
<name>MM Nau</name>
</json:item>
<json:item>
<name>AF Gazdar</name>
</json:item>
</author>
<host>
<volume>7</volume>
<pages>
<last>749</last>
<first>743</first>
</pages>
<author></author>
<title>Oncogene</title>
</host>
<title>Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation</title>
</json:item>
<json:item>
<author>
<json:item>
<name>JC Bourdon</name>
</json:item>
</author>
<host>
<volume>97</volume>
<pages>
<last>282</last>
<first>277</first>
</pages>
<author></author>
<title>Br J Cancer</title>
</host>
<title>p53 and its isoforms in cancer</title>
</json:item>
<json:item>
<author>
<json:item>
<name>SC Brownhill</name>
</json:item>
<json:item>
<name>C Taylor</name>
</json:item>
<json:item>
<name>SA Burchill</name>
</json:item>
</author>
<host>
<volume>96</volume>
<pages>
<last>1923</last>
<first>1914</first>
</pages>
<author></author>
<title>Br J Cancer</title>
</host>
<title>Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT</title>
</json:item>
<json:item>
<author>
<json:item>
<name>OS Bruland</name>
</json:item>
<json:item>
<name>O Fodstad</name>
</json:item>
<json:item>
<name>AE Stenwig</name>
</json:item>
<json:item>
<name>A Pihl</name>
</json:item>
</author>
<host>
<volume>48</volume>
<pages>
<last>5309</last>
<first>5302</first>
</pages>
<author></author>
<title>Cancer Res</title>
</host>
<title>Expression and characteristics of a novel human osteosarcoma‐associated cell surface antigen</title>
</json:item>
<json:item>
<author>
<json:item>
<name>N Chandar</name>
</json:item>
<json:item>
<name>B Billig</name>
</json:item>
<json:item>
<name>J McMaster</name>
</json:item>
<json:item>
<name>J Novak</name>
</json:item>
</author>
<host>
<volume>65</volume>
<pages>
<last>214</last>
<first>208</first>
</pages>
<author></author>
<title>Br J Cancer</title>
</host>
<title>Inactivation of p53 gene in human and murine osteosarcoma cells</title>
</json:item>
<json:item>
<author>
<json:item>
<name>E De Alava</name>
</json:item>
<json:item>
<name>CR Antonescu</name>
</json:item>
<json:item>
<name>A Panizo</name>
</json:item>
<json:item>
<name>D Leung</name>
</json:item>
<json:item>
<name>PA Meyers</name>
</json:item>
<json:item>
<name>AG Huvos</name>
</json:item>
<json:item>
<name>FJ Pardo‐Mindán</name>
</json:item>
<json:item>
<name>JH Healey</name>
</json:item>
<json:item>
<name>M Ladanyi</name>
</json:item>
</author>
<host>
<volume>89</volume>
<pages>
<last>792</last>
<first>783</first>
</pages>
<author></author>
<title>Cancer</title>
</host>
<title>Prognostic impact of P53 status in Ewing sarcoma</title>
</json:item>
<json:item>
<author>
<json:item>
<name>D Domagk</name>
</json:item>
<json:item>
<name>KL Schaefer</name>
</json:item>
<json:item>
<name>M Eisenacher</name>
</json:item>
<json:item>
<name>Y Braun</name>
</json:item>
<json:item>
<name>DH Wai</name>
</json:item>
<json:item>
<name>C Schleicher</name>
</json:item>
<json:item>
<name>R Diallo‐Danebrock</name>
</json:item>
<json:item>
<name>H Bojar</name>
</json:item>
<json:item>
<name>G Roeder</name>
</json:item>
<json:item>
<name>HE Gabbert</name>
</json:item>
<json:item>
<name>W Domschke</name>
</json:item>
<json:item>
<name>C Poremba</name>
</json:item>
</author>
<host>
<volume>17</volume>
<pages>
<last>407</last>
<first>399</first>
</pages>
<author></author>
<title>Oncol Rep</title>
</host>
<title>Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci</title>
</json:item>
<json:item>
<author>
<json:item>
<name>H Fiegler</name>
</json:item>
<json:item>
<name>P Carr</name>
</json:item>
<json:item>
<name>EJ Douglas</name>
</json:item>
<json:item>
<name>DC Burford</name>
</json:item>
<json:item>
<name>S Hunt</name>
</json:item>
<json:item>
<name>CE Scott</name>
</json:item>
<json:item>
<name>J Smith</name>
</json:item>
<json:item>
<name>D Vetrie</name>
</json:item>
<json:item>
<name>P Gorman</name>
</json:item>
<json:item>
<name>IP Tomlinson</name>
</json:item>
<json:item>
<name>NP Carter</name>
</json:item>
</author>
<host>
<volume>36</volume>
<pages>
<last>374</last>
<first>361</first>
</pages>
<author></author>
<title>Genes Chromosomes Cancer</title>
</host>
<title>DNA microarrays for comparative genomic hybridization based on DOP‐PCR amplification of BAC and PAC clones</title>
</json:item>
<json:item>
<author>
<json:item>
<name>N Friedrichs</name>
</json:item>
<json:item>
<name>L Kriegl</name>
</json:item>
<json:item>
<name>C Poremba</name>
</json:item>
<json:item>
<name>KL Schaefer</name>
</json:item>
<json:item>
<name>HE Gabbert</name>
</json:item>
<json:item>
<name>A Shimomura</name>
</json:item>
<json:item>
<name>E Paggen</name>
</json:item>
<json:item>
<name>S Merkelbach‐Bruse</name>
</json:item>
<json:item>
<name>R Buettner</name>
</json:item>
</author>
<host>
<volume>15</volume>
<pages>
<last>89</last>
<first>83</first>
</pages>
<author></author>
<title>Diagn Mol Pathol</title>
</host>
<title>Pitfalls in the detection of t(11;22) translocation by fluorescence in situ hybridization and RT‐PCR: A single‐blinded study</title>
</json:item>
<json:item>
<author>
<json:item>
<name>O Fodstad</name>
</json:item>
<json:item>
<name>A Brøgger</name>
</json:item>
<json:item>
<name>O Bruland</name>
</json:item>
<json:item>
<name>OP Solheim</name>
</json:item>
<json:item>
<name>JM Nesland</name>
</json:item>
<json:item>
<name>A Pihl</name>
</json:item>
</author>
<host>
<volume>38</volume>
<pages>
<last>40</last>
<first>33</first>
</pages>
<author></author>
<title>Int J Cancer</title>
</host>
<title>Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma</title>
</json:item>
<json:item>
<author>
<json:item>
<name>LA Garraway</name>
</json:item>
<json:item>
<name>HR Widlund</name>
</json:item>
<json:item>
<name>MA Rubin</name>
</json:item>
<json:item>
<name>G Getz</name>
</json:item>
<json:item>
<name>AJ Berger</name>
</json:item>
<json:item>
<name>S Ramaswamy</name>
</json:item>
<json:item>
<name>R Beroukhim</name>
</json:item>
<json:item>
<name>DA Milner</name>
</json:item>
<json:item>
<name>SR Granter</name>
</json:item>
<json:item>
<name>J Du</name>
</json:item>
<json:item>
<name>C Lee</name>
</json:item>
<json:item>
<name>SN Wagner</name>
</json:item>
<json:item>
<name>C Li</name>
</json:item>
<json:item>
<name>TR Golub</name>
</json:item>
<json:item>
<name>DL Rimm</name>
</json:item>
<json:item>
<name>ML Meyerson</name>
</json:item>
<json:item>
<name>DE Fisher</name>
</json:item>
<json:item>
<name>WR Sellers</name>
</json:item>
</author>
<host>
<volume>436</volume>
<pages>
<last>122</last>
<first>117</first>
</pages>
<author></author>
<title>Nature</title>
</host>
<title>Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma</title>
</json:item>
<json:item>
<author>
<json:item>
<name>R Gil‐Benso</name>
</json:item>
<json:item>
<name>C Lopez‐Gines</name>
</json:item>
<json:item>
<name>JA López‐Guerrero</name>
</json:item>
<json:item>
<name>C Carda</name>
</json:item>
<json:item>
<name>RC Callaghan</name>
</json:item>
<json:item>
<name>S Navarro</name>
</json:item>
<json:item>
<name>J Ferrer</name>
</json:item>
<json:item>
<name>A Pellín</name>
</json:item>
<json:item>
<name>A Llombart‐Bosch</name>
</json:item>
</author>
<host>
<volume>83</volume>
<pages>
<last>887</last>
<first>877</first>
</pages>
<author></author>
<title>Lab Invest</title>
</host>
<title>Establishment and characterization of a continuous human chondrosarcoma cell line, ch‐2879: Comparative histologic and genetic studies with its tumor of origin</title>
</json:item>
<json:item>
<author>
<json:item>
<name>RT Greenlee</name>
</json:item>
<json:item>
<name>MB Hill‐Harmon</name>
</json:item>
<json:item>
<name>T Murray</name>
</json:item>
<json:item>
<name>M Thun</name>
</json:item>
</author>
<host>
<volume>51</volume>
<pages>
<last>36</last>
<first>15</first>
</pages>
<author></author>
<title>CA Cancer J Clin</title>
</host>
<title>Cancer statistics</title>
</json:item>
<json:item>
<author>
<json:item>
<name>PA Hall</name>
</json:item>
<json:item>
<name>WG McCluggage</name>
</json:item>
</author>
<host>
<volume>208</volume>
<pages>
<last>6</last>
<first>1</first>
</pages>
<author></author>
<title>J Pathol</title>
</host>
<title>Assessing p53 in clinical contexts: Unlearned lessons and new perspectives</title>
</json:item>
<json:item>
<author>
<json:item>
<name>LJ Helman</name>
</json:item>
<json:item>
<name>P Meltzer</name>
</json:item>
</author>
<host>
<volume>3</volume>
<pages>
<last>694</last>
<first>685</first>
</pages>
<author></author>
<title>Nat Rev Cancer</title>
</host>
<title>Mechanisms of sarcoma development</title>
</json:item>
<json:item>
<author>
<json:item>
<name>J Henriksen</name>
</json:item>
<json:item>
<name>T Aagesen</name>
</json:item>
<json:item>
<name>GM Maelandsmo</name>
</json:item>
<json:item>
<name>RA Lothe</name>
</json:item>
<json:item>
<name>O Myklebost</name>
</json:item>
<json:item>
<name>A Forus</name>
</json:item>
</author>
<host>
<volume>22</volume>
<pages>
<last>5361</last>
<first>5358</first>
</pages>
<author></author>
<title>Oncogene</title>
</host>
<title>Amplification and overexpression of COPS3potentially target TP53 for proteasome‐mediated degradation</title>
</json:item>
<json:item>
<author>
<json:item>
<name>PJ Hensler</name>
</json:item>
<json:item>
<name>LA Annab</name>
</json:item>
<json:item>
<name>JC Barrett</name>
</json:item>
<json:item>
<name>OM Pereira‐Smith</name>
</json:item>
</author>
<host>
<volume>14</volume>
<pages>
<last>2297</last>
<first>2291</first>
</pages>
<author></author>
<title>Mol Cell Biol</title>
</host>
<title>A gene involved in control of human cellular senescence on human chromosome 1q</title>
</json:item>
<json:item>
<author>
<json:item>
<name>HY Huang</name>
</json:item>
<json:item>
<name>PB Illei</name>
</json:item>
<json:item>
<name>Z Zhao</name>
</json:item>
<json:item>
<name>M Mazumdar</name>
</json:item>
<json:item>
<name>AG Huvos</name>
</json:item>
<json:item>
<name>JH Healey</name>
</json:item>
<json:item>
<name>LH Wexler</name>
</json:item>
<json:item>
<name>R Gorlick</name>
</json:item>
<json:item>
<name>P Meyers</name>
</json:item>
<json:item>
<name>M Ladanyi</name>
</json:item>
</author>
<host>
<volume>23</volume>
<pages>
<last>558</last>
<first>548</first>
</pages>
<author></author>
<title>J Clin Oncol</title>
</host>
<title>Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: A highly lethal subset associated with poor chemoresponse</title>
</json:item>
<json:item>
<author>
<json:item>
<name>K Honoki</name>
</json:item>
<json:item>
<name>E Stojanovski</name>
</json:item>
<json:item>
<name>M McEvoy</name>
</json:item>
<json:item>
<name>H Fujii</name>
</json:item>
<json:item>
<name>T Tsujiuchi</name>
</json:item>
<json:item>
<name>A Kido</name>
</json:item>
<json:item>
<name>Y Takakura</name>
</json:item>
<json:item>
<name>J Attia</name>
</json:item>
</author>
<host>
<volume>110</volume>
<pages>
<last>1360</last>
<first>1351</first>
</pages>
<author></author>
<title>Cancer</title>
</host>
<title>Prognostic significance of p16 INK4a alteration for Ewing sarcoma: A meta‐analysis</title>
</json:item>
<json:item>
<author>
<json:item>
<name>AA Jagasia</name>
</json:item>
<json:item>
<name>JA Block</name>
</json:item>
<json:item>
<name>A Qureshi</name>
</json:item>
<json:item>
<name>MO Diaz</name>
</json:item>
<json:item>
<name>T Nobori</name>
</json:item>
<json:item>
<name>S Gitelis</name>
</json:item>
<json:item>
<name>AP Iyer</name>
</json:item>
</author>
<host>
<volume>105</volume>
<pages>
<last>103</last>
<first>91</first>
</pages>
<author></author>
<title>Cancer Lett</title>
</host>
<title>Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas</title>
</json:item>
<json:item>
<author>
<json:item>
<name>I Kjønniksen</name>
</json:item>
<json:item>
<name>M Winderen</name>
</json:item>
<json:item>
<name>O Bruland</name>
</json:item>
<json:item>
<name>O Fodstad</name>
</json:item>
</author>
<host>
<volume>54</volume>
<pages>
<last>1719</last>
<first>1715</first>
</pages>
<author></author>
<title>Cancer Res</title>
</host>
<title>Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats</title>
</json:item>
<json:item>
<author>
<json:item>
<name>J Knijnenburg</name>
</json:item>
<json:item>
<name>K Szuhai</name>
</json:item>
<json:item>
<name>J Giltay</name>
</json:item>
<json:item>
<name>L Molenaar</name>
</json:item>
<json:item>
<name>W Sloos</name>
</json:item>
<json:item>
<name>M Poot</name>
</json:item>
<json:item>
<name>HJ Tanke</name>
</json:item>
<json:item>
<name>C Rosenberg</name>
</json:item>
</author>
<host>
<volume>132A</volume>
<pages>
<last>40</last>
<first>36</first>
</pages>
<author></author>
<title>Am J Med Genet A</title>
</host>
<title>Insights from genomic microarrays into structural chromosome rearrangements</title>
</json:item>
<json:item>
<author>
<json:item>
<name>H Kovar</name>
</json:item>
<json:item>
<name>A Auinger</name>
</json:item>
<json:item>
<name>G Jug</name>
</json:item>
<json:item>
<name>D Aryee</name>
</json:item>
<json:item>
<name>A Zoubek</name>
</json:item>
<json:item>
<name>M Salzer‐Kuntschik</name>
</json:item>
<json:item>
<name>H Gadner</name>
</json:item>
</author>
<host>
<volume>8</volume>
<pages>
<last>2690</last>
<first>2683</first>
</pages>
<author></author>
<title>Oncogene</title>
</host>
<title>Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours</title>
</json:item>
<json:item>
<author>
<json:item>
<name>H Kovar</name>
</json:item>
<json:item>
<name>G Jug</name>
</json:item>
<json:item>
<name>DN Aryee</name>
</json:item>
<json:item>
<name>A Zoubek</name>
</json:item>
<json:item>
<name>P Ambros</name>
</json:item>
<json:item>
<name>B Gruber</name>
</json:item>
<json:item>
<name>R Windhager</name>
</json:item>
<json:item>
<name>H Gadner</name>
</json:item>
</author>
<host>
<volume>15</volume>
<pages>
<last>2232</last>
<first>2225</first>
</pages>
<author></author>
<title>Oncogene</title>
</host>
<title>Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors</title>
</json:item>
<json:item>
<author>
<json:item>
<name>A Maitra</name>
</json:item>
<json:item>
<name>H Roberts</name>
</json:item>
<json:item>
<name>AG Weinberg</name>
</json:item>
<json:item>
<name>J Geradts</name>
</json:item>
</author>
<host>
<volume>95</volume>
<pages>
<last>38</last>
<first>34</first>
</pages>
<author></author>
<title>Int J Cancer</title>
</host>
<title>Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas</title>
</json:item>
<json:item>
<author>
<json:item>
<name>I Meinhold‐Heerlein</name>
</json:item>
<json:item>
<name>E Ninci</name>
</json:item>
<json:item>
<name>H Ikenberg</name>
</json:item>
<json:item>
<name>T Brandstetter</name>
</json:item>
<json:item>
<name>C Ihling</name>
</json:item>
<json:item>
<name>I Schwenk</name>
</json:item>
<json:item>
<name>A Straub</name>
</json:item>
<json:item>
<name>B Schmitt</name>
</json:item>
<json:item>
<name>H Bettendorf</name>
</json:item>
<json:item>
<name>R Iggo</name>
</json:item>
<json:item>
<name>T Bauknecht</name>
</json:item>
</author>
<host>
<volume>60</volume>
<pages>
<last>188</last>
<first>176</first>
</pages>
<author></author>
<title>Oncology</title>
</host>
<title>Evaluation of methods to detect p53 mutations in ovarian cancer</title>
</json:item>
<json:item>
<author>
<json:item>
<name>J Momand</name>
</json:item>
<json:item>
<name>D Jung</name>
</json:item>
<json:item>
<name>S Wilczynski</name>
</json:item>
<json:item>
<name>J Niland</name>
</json:item>
</author>
<host>
<volume>26</volume>
<pages>
<last>3459</last>
<first>3453</first>
</pages>
<author></author>
<title>Nucleic Acids Res</title>
</host>
<title>The MDM2 gene amplification database</title>
</json:item>
<json:item>
<author>
<json:item>
<name>WA Nelson‐Rees</name>
</json:item>
<json:item>
<name>DW Daniels</name>
</json:item>
<json:item>
<name>RR Flandermeyer</name>
</json:item>
</author>
<host>
<volume>212</volume>
<pages>
<last>452</last>
<first>446</first>
</pages>
<author></author>
<title>Science</title>
</host>
<title>Cross‐contamination of cells in culture</title>
</json:item>
<json:item>
<author>
<json:item>
<name>P Ouyang</name>
</json:item>
</author>
<host>
<volume>246</volume>
<pages>
<last>776</last>
<first>771</first>
</pages>
<author></author>
<title>Biochem Biophys Res Commun</title>
</host>
<title>An in vitro model to study mesenchymal‐epithelial transformation</title>
</json:item>
<json:item>
<author>
<json:item>
<name>EE Pakos</name>
</json:item>
<json:item>
<name>PA Kyzas</name>
</json:item>
<json:item>
<name>JP Ioannidis</name>
</json:item>
</author>
<host>
<volume>10</volume>
<pages>
<last>6214</last>
<first>6208</first>
</pages>
<author></author>
<title>Clin Cancer Res</title>
</host>
<title>Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta‐analysis</title>
</json:item>
<json:item>
<author>
<json:item>
<name>S Pelotti</name>
</json:item>
<json:item>
<name>S Ceccardi</name>
</json:item>
<json:item>
<name>M Alù</name>
</json:item>
<json:item>
<name>F Lugaresi</name>
</json:item>
<json:item>
<name>R Trane</name>
</json:item>
<json:item>
<name>M Falconi</name>
</json:item>
<json:item>
<name>C Bini</name>
</json:item>
<json:item>
<name> Cicognani</name>
</json:item>
</author>
<host>
<volume>11</volume>
<pages>
<last>400</last>
<first>397</first>
</pages>
<author></author>
<title>Genet Test</title>
</host>
<title>Cancerous tissues in forensic genetic analysis</title>
</json:item>
<json:item>
<author>
<json:item>
<name>M Peter</name>
</json:item>
<json:item>
<name>J Couturier</name>
</json:item>
<json:item>
<name>H Pacquement</name>
</json:item>
<json:item>
<name>J Michon</name>
</json:item>
<json:item>
<name>G Thomas</name>
</json:item>
<json:item>
<name>H Magdelenat</name>
</json:item>
<json:item>
<name>O Delattre</name>
</json:item>
</author>
<host>
<volume>14</volume>
<pages>
<last>1164</last>
<first>1159</first>
</pages>
<author></author>
<title>Oncogene</title>
</host>
<title>A new member of the ETS family fused to EWS in Ewing tumors</title>
</json:item>
<json:item>
<author>
<json:item>
<name>JS Rhim</name>
</json:item>
<json:item>
<name>DL Putman</name>
</json:item>
<json:item>
<name>P Arnstein</name>
</json:item>
<json:item>
<name>RJ Huebner</name>
</json:item>
<json:item>
<name>RM McAllister</name>
</json:item>
</author>
<host>
<volume>19</volume>
<pages>
<last>510</last>
<first>505</first>
</pages>
<author></author>
<title>Int J Cancer</title>
</host>
<title>Characterization of human cells transformed in vitro by N‐methyl‐N'‐nitro‐N‐nitrosoguanidine</title>
</json:item>
<json:item>
<author>
<json:item>
<name>AA Sandberg</name>
</json:item>
<json:item>
<name>JA Bridge</name>
</json:item>
</author>
<host>
<volume>145</volume>
<pages>
<last>30</last>
<first>1</first>
</pages>
<author></author>
<title>Cancer Genet Cytogenet</title>
</host>
<title>Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and relatcd tumors</title>
</json:item>
<json:item>
<author>
<json:item>
<name>S Savola</name>
</json:item>
<json:item>
<name>F Nardi</name>
</json:item>
<json:item>
<name>K Scotlandi</name>
</json:item>
<json:item>
<name>P Picci</name>
</json:item>
<json:item>
<name>S Knuutila</name>
</json:item>
</author>
<host>
<volume>119</volume>
<pages>
<last>26</last>
<first>21</first>
</pages>
<author></author>
<title>Cytogenet Genome Res</title>
</host>
<title>Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma</title>
</json:item>
<json:item>
<author>
<json:item>
<name>KL Schaefer</name>
</json:item>
<json:item>
<name>D Wai</name>
</json:item>
<json:item>
<name>C Poremba</name>
</json:item>
<json:item>
<name>R Diallo</name>
</json:item>
<json:item>
<name>W Boecker</name>
</json:item>
<json:item>
<name>B Dockhorn‐Dworniczak</name>
</json:item>
</author>
<host>
<volume>38</volume>
<pages>
<last>253</last>
<first>247</first>
</pages>
<author></author>
<title>Med Pediatr Oncol</title>
</host>
<title>Analysis of TP53 germline mutations in pediatric tumor patients using DNA microarray‐based sequencing technology</title>
</json:item>
<json:item>
<author>
<json:item>
<name>KL Schaefer</name>
</json:item>
<json:item>
<name>M Eisenacher</name>
</json:item>
<json:item>
<name>Y Braun</name>
</json:item>
<json:item>
<name>K Brachwitz</name>
</json:item>
<json:item>
<name>DH Wai</name>
</json:item>
<json:item>
<name>U Dirksen</name>
</json:item>
<json:item>
<name>C Lanvers‐Kaminsky</name>
</json:item>
<json:item>
<name>H Juergens</name>
</json:item>
<json:item>
<name>D Herrero</name>
</json:item>
<json:item>
<name>S Stegmaier</name>
</json:item>
<json:item>
<name>E Koscielniak</name>
</json:item>
<json:item>
<name>A Eggert</name>
</json:item>
<json:item>
<name>M Nathrath</name>
</json:item>
<json:item>
<name>G Gosheger</name>
</json:item>
<json:item>
<name>DT Schneider</name>
</json:item>
<json:item>
<name>C Bury</name>
</json:item>
<json:item>
<name>R Diallo‐Danebrock</name>
</json:item>
<json:item>
<name>L Ottaviano</name>
</json:item>
<json:item>
<name>HE Gabbert</name>
</json:item>
<json:item>
<name>C Poremba</name>
</json:item>
</author>
<host>
<volume>44</volume>
<pages>
<last>709</last>
<first>699</first>
</pages>
<author></author>
<title>Eur J Cancer</title>
</host>
<title>Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy</title>
</json:item>
<json:item>
<author>
<json:item>
<name>JP Schouten</name>
</json:item>
<json:item>
<name>CJ McElgunn</name>
</json:item>
<json:item>
<name>R Waaijer</name>
</json:item>
<json:item>
<name>D Zwijnenburg</name>
</json:item>
<json:item>
<name>F Diepvens</name>
</json:item>
<json:item>
<name>G Pals</name>
</json:item>
</author>
<host>
<volume>30</volume>
<pages>
<first>57</first>
</pages>
<author></author>
<title>Nucleic Acids Res</title>
</host>
<title>Relative quantification of 40 nucleic acid sequences by multiplex ligation‐dependent probe amplification</title>
</json:item>
<json:item>
<author>
<json:item>
<name>A Schulz</name>
</json:item>
<json:item>
<name>A Battmann</name>
</json:item>
<json:item>
<name>CM Heinrichs</name>
</json:item>
<json:item>
<name>A Kern</name>
</json:item>
<json:item>
<name>A Tiedemann</name>
</json:item>
<json:item>
<name>H Bürger</name>
</json:item>
<json:item>
<name>B Fohr</name>
</json:item>
<json:item>
<name>N Hani</name>
</json:item>
<json:item>
<name>C Pietruck</name>
</json:item>
<json:item>
<name>H Busk</name>
</json:item>
<json:item>
<name>G Jundt</name>
</json:item>
</author>
<host>
<volume>52</volume>
<pages>
<first>30</first>
</pages>
<author></author>
<title>Calcif Tissue Int</title>
</host>
<title>Properties and reactivity of a new human osteosarcoma cell line (HOS 58)</title>
</json:item>
<json:item>
<author>
<json:item>
<name>KM Skubitz</name>
</json:item>
<json:item>
<name>DR D'Adamo</name>
</json:item>
</author>
<host>
<volume>82</volume>
<pages>
<last>1432</last>
<first>1409</first>
</pages>
<author></author>
<title>Mayo Clin Proc</title>
</host>
<title>Sarcoma</title>
</json:item>
<json:item>
<author>
<json:item>
<name>VV Ternovoi</name>
</json:item>
<json:item>
<name>DT Curiel</name>
</json:item>
<json:item>
<name>BF Smith</name>
</json:item>
<json:item>
<name>GP Siegal</name>
</json:item>
</author>
<host>
<volume>86</volume>
<pages>
<last>766</last>
<first>748</first>
</pages>
<author></author>
<title>Lab Invest</title>
</host>
<title>Adenovirus‐mediated p53 tumor suppressor gene therapy of osteosarcoma</title>
</json:item>
<json:item>
<author>
<json:item>
<name>F Urano</name>
</json:item>
<json:item>
<name>A Umezawa</name>
</json:item>
<json:item>
<name>H Yabe</name>
</json:item>
<json:item>
<name>W Hong</name>
</json:item>
<json:item>
<name>K Yoshida</name>
</json:item>
<json:item>
<name>K Fujinaga</name>
</json:item>
<json:item>
<name>J Hata</name>
</json:item>
</author>
<host>
<volume>7</volume>
<pages>
<last>711</last>
<first>703</first>
</pages>
<author></author>
<title>Jpn J Cancer Res</title>
</host>
<title>Molecular analysis of Ewing's sarcoma: Another fusion gene, EWS‐E1AF, available for diagnosis</title>
</json:item>
<json:item>
<author>
<json:item>
<name>H van den Berg</name>
</json:item>
<json:item>
<name>HM Kroon</name>
</json:item>
<json:item>
<name>A Slaar</name>
</json:item>
<json:item>
<name>PCW Hogendoorn</name>
</json:item>
</author>
<host>
<volume>28</volume>
<pages>
<last>35</last>
<first>29</first>
</pages>
<author></author>
<title>J Pediatr Orthop</title>
</host>
<title>Incidence of biopsy‐proven bone tumors in children: A report based on the Dutch pathology registration “PALGA.”</title>
</json:item>
<json:item>
<author>
<json:item>
<name>F van Valen</name>
</json:item>
</author>
<host>
<volume>1</volume>
<pages>
<last>85</last>
<first>55</first>
</pages>
<author></author>
<title>Human Cell Culture</title>
</host>
<title>Ewing's sarcoma family of tumors</title>
</json:item>
<json:item>
<author>
<json:item>
<name>B Vogelstein</name>
</json:item>
<json:item>
<name>D Lane</name>
</json:item>
<json:item>
<name>AJ Levine</name>
</json:item>
</author>
<host>
<volume>408</volume>
<pages>
<last>310</last>
<first>307</first>
</pages>
<author></author>
<title>Nature</title>
</host>
<title>Surfing the p53 network</title>
</json:item>
<json:item>
<author>
<json:item>
<name>H Wang</name>
</json:item>
<json:item>
<name>S Huang</name>
</json:item>
<json:item>
<name>J Shou</name>
</json:item>
<json:item>
<name>EW Su</name>
</json:item>
<json:item>
<name>JE Onyia</name>
</json:item>
<json:item>
<name>B Liao</name>
</json:item>
<json:item>
<name>S Li</name>
</json:item>
</author>
<host>
<volume>7</volume>
<pages>
<first>166</first>
</pages>
<author></author>
<title>BMC Genomics</title>
</host>
<title>Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data</title>
</json:item>
<json:item>
<author>
<json:item>
<name>JS Wunder</name>
</json:item>
<json:item>
<name>N Gokgoz</name>
</json:item>
<json:item>
<name>R Parkes</name>
</json:item>
<json:item>
<name>SB Bull</name>
</json:item>
<json:item>
<name>S Eskandarian</name>
</json:item>
<json:item>
<name>AM Davis</name>
</json:item>
<json:item>
<name>CP Beauchamp</name>
</json:item>
<json:item>
<name>EU Conrad</name>
</json:item>
<json:item>
<name>RJ Grimer</name>
</json:item>
<json:item>
<name>JH Healey</name>
</json:item>
<json:item>
<name>D Malkin</name>
</json:item>
<json:item>
<name>DC Mangham</name>
</json:item>
<json:item>
<name>MJ Rock</name>
</json:item>
<json:item>
<name>RS Bell</name>
</json:item>
<json:item>
<name>IL Andrulis</name>
</json:item>
</author>
<host>
<volume>23</volume>
<pages>
<last>1490</last>
<first>1483</first>
</pages>
<author></author>
<title>J Clin Oncol</title>
</host>
<title>TP53 mutations and outcome in osteosarcoma: A prospective, multicenter study</title>
</json:item>
</refBibs>
<genre>
<json:string>article</json:string>
</genre>
<host>
<volume>49</volume>
<publisherId>
<json:string>GCC</json:string>
</publisherId>
<pages>
<total>12</total>
<last>51</last>
<first>40</first>
</pages>
<issn>
<json:string>1045-2257</json:string>
</issn>
<issue>1</issue>
<subject>
<json:item>
<value>Research Article</value>
</json:item>
</subject>
<genre>
<json:string>journal</json:string>
</genre>
<language>
<json:string>unknown</json:string>
</language>
<eissn>
<json:string>1098-2264</json:string>
</eissn>
<title>Genes, Chromosomes and Cancer</title>
<doi>
<json:string>10.1002/(ISSN)1098-2264</json:string>
</doi>
</host>
<categories>
<wos>
<json:string>science</json:string>
<json:string>oncology</json:string>
<json:string>genetics & heredity</json:string>
</wos>
<scienceMetrix>
<json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>oncology & carcinogenesis</json:string>
</scienceMetrix>
</categories>
<publicationDate>2010</publicationDate>
<copyrightDate>2010</copyrightDate>
<doi>
<json:string>10.1002/gcc.20717</json:string>
</doi>
<id>E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9</id>
<score>0.17562181</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main" xml:lang="en">Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability>
<p>Copyright © 2009 Wiley‐Liss, Inc.</p>
</availability>
<date>2010</date>
</publicationStmt>
<sourceDesc>
<biblStruct type="inbook">
<analytic>
<title level="a" type="main" xml:lang="en">Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
<author xml:id="author-1">
<persName>
<forename type="first">Laura</forename>
<surname>Ottaviano</surname>
</persName>
<note type="biography">Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</note>
<affiliation>Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</affiliation>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-2">
<persName>
<forename type="first">Karl‐Ludwig</forename>
<surname>Schaefer</surname>
</persName>
<note type="biography">Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</note>
<affiliation>Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</affiliation>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<affiliation>Institute of Pathology, Heinrich‐Heine‐University Duesseldorf, Germany, Moorenstr. 5, 40225 Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-3">
<persName>
<forename type="first">Melanie</forename>
<surname>Gajewski</surname>
</persName>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-4">
<persName>
<forename type="first">Wolfgang</forename>
<surname>Huckenbeck</surname>
</persName>
<affiliation>Institute of Forensic Medicine, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-5">
<persName>
<forename type="first">Stefan</forename>
<surname>Baldus</surname>
</persName>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-6">
<persName>
<forename type="first">Uwe</forename>
<surname>Rogel</surname>
</persName>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-7">
<persName>
<forename type="first">Carlos</forename>
<surname>Mackintosh</surname>
</persName>
<affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</affiliation>
</author>
<author xml:id="author-8">
<persName>
<forename type="first">Enrique</forename>
<surname>de Alava</surname>
</persName>
<affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</affiliation>
</author>
<author xml:id="author-9">
<persName>
<forename type="first">Ola</forename>
<surname>Myklebost</surname>
</persName>
<affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</affiliation>
</author>
<author xml:id="author-10">
<persName>
<forename type="first">Stine H.</forename>
<surname>Kresse</surname>
</persName>
<affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</affiliation>
</author>
<author xml:id="author-11">
<persName>
<forename type="first">Leonardo A.</forename>
<surname>Meza‐Zepeda</surname>
</persName>
<affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</affiliation>
</author>
<author xml:id="author-12">
<persName>
<forename type="first">Massimo</forename>
<surname>Serra</surname>
</persName>
<affiliation>Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy</affiliation>
</author>
<author xml:id="author-13">
<persName>
<forename type="first">Anne‐Marie</forename>
<surname>Cleton‐Jansen</surname>
</persName>
<affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</affiliation>
</author>
<author xml:id="author-14">
<persName>
<forename type="first">Pancras C. W.</forename>
<surname>Hogendoorn</surname>
</persName>
<affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</affiliation>
</author>
<author xml:id="author-15">
<persName>
<forename type="first">Horst</forename>
<surname>Buerger</surname>
</persName>
<affiliation>Institute of Pathology, University Medical Center Muenster, Muenster, Germany</affiliation>
</author>
<author xml:id="author-16">
<persName>
<forename type="first">Thomas</forename>
<surname>Aigner</surname>
</persName>
<affiliation>Institute of Pathology, University of Leipzig, Leipzig, Germany</affiliation>
</author>
<author xml:id="author-17">
<persName>
<forename type="first">Helmut E.</forename>
<surname>Gabbert</surname>
</persName>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
</author>
<author xml:id="author-18">
<persName>
<forename type="first">Christopher</forename>
<surname>Poremba</surname>
</persName>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<affiliation>Center of Histopathology, Cytology and Molecular Diagnostics (CHCMD), Research Park Trier, Trier, Germany</affiliation>
</author>
</analytic>
<monogr>
<title level="j">Genes, Chromosomes and Cancer</title>
<title level="j" type="abbrev">Genes Chromosom. Cancer</title>
<idno type="pISSN">1045-2257</idno>
<idno type="eISSN">1098-2264</idno>
<idno type="DOI">10.1002/(ISSN)1098-2264</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01"></date>
<biblScope unit="volume">49</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="40">40</biblScope>
<biblScope unit="page" to="51">51</biblScope>
</imprint>
</monogr>
<idno type="istex">E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9</idno>
<idno type="DOI">10.1002/gcc.20717</idno>
<idno type="ArticleID">GCC20717</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<creation>
<date>2010</date>
</creation>
<langUsage>
<language ident="en">en</language>
</langUsage>
<abstract xml:lang="en">
<p>Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of CDKN2A as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the TP53 gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53. TP53wt cell lines usually expressed the protein in 2–10% of the cells. However, seven TP53wt osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for CDKN2A and TP53, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable. © 2009 Wiley‐Liss, Inc.</p>
</abstract>
<textClass>
<keywords scheme="Journal Subject">
<list>
<head>article-category</head>
<item>
<term>Research Article</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc>
<change when="2009-06-04">Received</change>
<change when="2009-06-28">Registration</change>
<change when="2010-01">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley, elements deleted: body">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1098-2264</doi>
<issn type="print">1045-2257</issn>
<issn type="electronic">1098-2264</issn>
<idGroup>
<id type="product" value="GCC"></id>
</idGroup>
<titleGroup>
<title type="main" xml:lang="en" sort="GENES, CHROMOSOMES AND CANCER">Genes, Chromosomes and Cancer</title>
<title type="short">Genes Chromosom. Cancer</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="10">
<doi origin="wiley" registered="yes">10.1002/gcc.v49:1</doi>
<numberingGroup>
<numbering type="journalVolume" number="49">49</numbering>
<numbering type="journalIssue">1</numbering>
</numberingGroup>
<coverDate startDate="2010-01">January 2010</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="50" status="forIssue">
<doi origin="wiley" registered="yes">10.1002/gcc.20717</doi>
<idGroup>
<id type="unit" value="GCC20717"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="12"></count>
</countGroup>
<titleGroup>
<title type="articleCategory">Research Article</title>
<title type="tocHeading1">Research Articles</title>
</titleGroup>
<copyright ownership="publisher">Copyright © 2009 Wiley‐Liss, Inc.</copyright>
<eventGroup>
<event type="manuscriptReceived" date="2009-06-04"></event>
<event type="manuscriptAccepted" date="2009-06-28"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2009-09-29"></event>
<event type="firstOnline" date="2009-09-29"></event>
<event type="publishedOnlineFinalForm" date="2009-11-09"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-25"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst">40</numbering>
<numbering type="pageLast">51</numbering>
</numberingGroup>
<correspondenceTo>Institute of Pathology, Heinrich‐Heine‐University Duesseldorf, Germany, Moorenstr. 5, 40225 Duesseldorf, Germany</correspondenceTo>
<linkGroup>
<link type="toTypesetVersion" href="file:GCC.GCC20717.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<countGroup>
<count type="figureTotal" number="1"></count>
<count type="tableTotal" number="3"></count>
<count type="referenceTotal" number="49"></count>
<count type="wordTotal" number="9482"></count>
</countGroup>
<titleGroup>
<title type="main" xml:lang="en">Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
<title type="short" xml:lang="en">Characterization of Bone Tumor Cell Lines</title>
</titleGroup>
<creators>
<creator xml:id="au1" creatorRole="author" affiliationRef="#af1" noteRef="#fn1">
<personName>
<givenNames>Laura</givenNames>
<familyName>Ottaviano</familyName>
</personName>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes" noteRef="#fn1">
<personName>
<givenNames>Karl‐Ludwig</givenNames>
<familyName>Schaefer</familyName>
</personName>
<contactDetails>
<email normalForm="l.schaefer@med.uni-duesseldorf.de">l.schaefer@med.uni‐duesseldorf.de</email>
</contactDetails>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af1">
<personName>
<givenNames>Melanie</givenNames>
<familyName>Gajewski</familyName>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af2">
<personName>
<givenNames>Wolfgang</givenNames>
<familyName>Huckenbeck</familyName>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af1">
<personName>
<givenNames>Stefan</givenNames>
<familyName>Baldus</familyName>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af1">
<personName>
<givenNames>Uwe</givenNames>
<familyName>Rogel</familyName>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af3">
<personName>
<givenNames>Carlos</givenNames>
<familyName>Mackintosh</familyName>
</personName>
</creator>
<creator xml:id="au8" creatorRole="author" affiliationRef="#af3">
<personName>
<givenNames>Enrique</givenNames>
<familyName>de Alava</familyName>
</personName>
</creator>
<creator xml:id="au9" creatorRole="author" affiliationRef="#af4">
<personName>
<givenNames>Ola</givenNames>
<familyName>Myklebost</familyName>
</personName>
</creator>
<creator xml:id="au10" creatorRole="author" affiliationRef="#af4">
<personName>
<givenNames>Stine H.</givenNames>
<familyName>Kresse</familyName>
</personName>
</creator>
<creator xml:id="au11" creatorRole="author" affiliationRef="#af4">
<personName>
<givenNames>Leonardo A.</givenNames>
<familyName>Meza‐Zepeda</familyName>
</personName>
</creator>
<creator xml:id="au12" creatorRole="author" affiliationRef="#af5">
<personName>
<givenNames>Massimo</givenNames>
<familyName>Serra</familyName>
</personName>
</creator>
<creator xml:id="au13" creatorRole="author" affiliationRef="#af6">
<personName>
<givenNames>Anne‐Marie</givenNames>
<familyName>Cleton‐Jansen</familyName>
</personName>
</creator>
<creator xml:id="au14" creatorRole="author" affiliationRef="#af6">
<personName>
<givenNames>Pancras C. W.</givenNames>
<familyName>Hogendoorn</familyName>
</personName>
</creator>
<creator xml:id="au15" creatorRole="author" affiliationRef="#af7">
<personName>
<givenNames>Horst</givenNames>
<familyName>Buerger</familyName>
</personName>
</creator>
<creator xml:id="au16" creatorRole="author" affiliationRef="#af8">
<personName>
<givenNames>Thomas</givenNames>
<familyName>Aigner</familyName>
</personName>
</creator>
<creator xml:id="au17" creatorRole="author" affiliationRef="#af1">
<personName>
<givenNames>Helmut E.</givenNames>
<familyName>Gabbert</familyName>
</personName>
</creator>
<creator xml:id="au18" creatorRole="author" affiliationRef="#af1 #af9">
<personName>
<givenNames>Christopher</givenNames>
<familyName>Poremba</familyName>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="af1" countryCode="DE" type="organization">
<unparsedAffiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="DE" type="organization">
<unparsedAffiliation>Institute of Forensic Medicine, University Medical Center Duesseldorf, Duesseldorf, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="ES" type="organization">
<unparsedAffiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="NO" type="organization">
<unparsedAffiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="IT" type="organization">
<unparsedAffiliation>Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af6" countryCode="NL" type="organization">
<unparsedAffiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af7" countryCode="DE" type="organization">
<unparsedAffiliation>Institute of Pathology, University Medical Center Muenster, Muenster, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af8" countryCode="DE" type="organization">
<unparsedAffiliation>Institute of Pathology, University of Leipzig, Leipzig, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af9" countryCode="DE" type="organization">
<unparsedAffiliation>Center of Histopathology, Cytology and Molecular Diagnostics (CHCMD), Research Park Trier, Trier, Germany</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<supportingInformation>
<p> Additional Supporting Information may be found in the online version of this article. </p>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:10452257:media:gcc20717:GCC_20717_sm_suppinfotable1"></mediaResource>
<caption>Supporting Information Table 1</caption>
</supportingInfoItem>
</supportingInformation>
<abstractGroup>
<abstract type="main" xml:lang="en">
<title type="main">Abstract</title>
<p>Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of
<i>CDKN2A</i>
as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the
<i>TP53</i>
gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53.
<i>TP53</i>
<sup>wt</sup>
cell lines usually expressed the protein in 2–10% of the cells. However, seven
<i>TP53</i>
<sup>wt</sup>
osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for
<i>CDKN2A</i>
and
<i>TP53</i>
, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable. © 2009 Wiley‐Liss, Inc.</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup>
<note xml:id="fn1">
<label></label>
<p>Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en">
<title>Characterization of Bone Tumor Cell Lines</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort</title>
</titleInfo>
<name type="personal">
<namePart type="given">Laura</namePart>
<namePart type="family">Ottaviano</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<description>Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</description>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Karl‐Ludwig</namePart>
<namePart type="family">Schaefer</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<description>Laura Ottaviano and Karl‐Ludwig Schaefer contributed equally to this study.</description>
<affiliation>Institute of Pathology, Heinrich‐Heine‐University Duesseldorf, Germany, Moorenstr. 5, 40225 Duesseldorf, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Melanie</namePart>
<namePart type="family">Gajewski</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Wolfgang</namePart>
<namePart type="family">Huckenbeck</namePart>
<affiliation>Institute of Forensic Medicine, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Stefan</namePart>
<namePart type="family">Baldus</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Uwe</namePart>
<namePart type="family">Rogel</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Carlos</namePart>
<namePart type="family">Mackintosh</namePart>
<affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Enrique</namePart>
<namePart type="family">de Alava</namePart>
<affiliation>Centro de Investigación del Cáncer‐IBMCC, Universidad de Salamanca‐CSIC, Salamanca, Spain</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Ola</namePart>
<namePart type="family">Myklebost</namePart>
<affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Stine H.</namePart>
<namePart type="family">Kresse</namePart>
<affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Leonardo A.</namePart>
<namePart type="family">Meza‐Zepeda</namePart>
<affiliation>Department of Tumor Biology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Massimo</namePart>
<namePart type="family">Serra</namePart>
<affiliation>Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Anne‐Marie</namePart>
<namePart type="family">Cleton‐Jansen</namePart>
<affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Pancras C. W.</namePart>
<namePart type="family">Hogendoorn</namePart>
<affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Horst</namePart>
<namePart type="family">Buerger</namePart>
<affiliation>Institute of Pathology, University Medical Center Muenster, Muenster, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Thomas</namePart>
<namePart type="family">Aigner</namePart>
<affiliation>Institute of Pathology, University of Leipzig, Leipzig, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Helmut E.</namePart>
<namePart type="family">Gabbert</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Christopher</namePart>
<namePart type="family">Poremba</namePart>
<affiliation>Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany</affiliation>
<affiliation>Center of Histopathology, Cytology and Molecular Diagnostics (CHCMD), Research Park Trier, Trier, Germany</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article"></genre>
<originInfo>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place>
<placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2010-01</dateIssued>
<dateCaptured encoding="w3cdtf">2009-06-04</dateCaptured>
<dateValid encoding="w3cdtf">2009-06-28</dateValid>
<copyrightDate encoding="w3cdtf">2010</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
<extent unit="figures">1</extent>
<extent unit="tables">3</extent>
<extent unit="references">49</extent>
<extent unit="words">9482</extent>
</physicalDescription>
<abstract lang="en">Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of CDKN2A as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the TP53 gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53. TP53wt cell lines usually expressed the protein in 2–10% of the cells. However, seven TP53wt osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for CDKN2A and TP53, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable. © 2009 Wiley‐Liss, Inc.</abstract>
<relatedItem type="host">
<titleInfo>
<title>Genes, Chromosomes and Cancer</title>
</titleInfo>
<titleInfo type="abbreviated">
<title>Genes Chromosom. Cancer</title>
</titleInfo>
<genre type="journal">journal</genre>
<note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information Table 1 - </note>
<subject>
<genre>article-category</genre>
<topic>Research Article</topic>
</subject>
<identifier type="ISSN">1045-2257</identifier>
<identifier type="eISSN">1098-2264</identifier>
<identifier type="DOI">10.1002/(ISSN)1098-2264</identifier>
<identifier type="PublisherID">GCC</identifier>
<part>
<date>2010</date>
<detail type="volume">
<caption>vol.</caption>
<number>49</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages">
<start>40</start>
<end>51</end>
<total>12</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9</identifier>
<identifier type="DOI">10.1002/gcc.20717</identifier>
<identifier type="ArticleID">GCC20717</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Wiley‐Liss, Inc.</accessCondition>
<recordInfo>
<recordContentSource>WILEY</recordContentSource>
<recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001916 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001916 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Rhénanie
   |area=    UnivTrevesV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:E8374F395D7E218EE22C21CB4F7C9DACF7D1C4D9
   |texte=   Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Jul 22 16:29:01 2017. Site generation: Wed Feb 28 14:55:37 2024